Beta Bionics, Inc. (NASDAQ:BBNX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Beta Bionics, Inc. (NASDAQ:BBNX) have been given a consensus rating of “Moderate Buy” by the thirteen research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $29.3333.

Several equities analysts have weighed in on the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $31.00 target price (up previously from $26.00) on shares of Beta Bionics in a research note on Wednesday, October 29th. Piper Sandler restated an “overweight” rating and set a $32.00 price target (up from $26.00) on shares of Beta Bionics in a report on Wednesday, October 29th. Robert W. Baird set a $28.00 price objective on shares of Beta Bionics in a research note on Tuesday, December 16th. Truist Financial increased their target price on shares of Beta Bionics from $32.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Beta Bionics in a report on Monday.

Beta Bionics Stock Performance

NASDAQ BBNX opened at $31.09 on Friday. The firm’s 50 day moving average price is $27.73 and its two-hundred day moving average price is $21.39. Beta Bionics has a twelve month low of $8.89 and a twelve month high of $32.71. The stock has a market cap of $1.37 billion and a price-to-earnings ratio of -7.11.

Beta Bionics (NASDAQ:BBNX) last issued its earnings results on Tuesday, October 28th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.12. Beta Bionics had a negative return on equity of 35.72% and a negative net margin of 87.89%.The business had revenue of $27.25 million during the quarter, compared to analysts’ expectations of $23.92 million.

Insider Transactions at Beta Bionics

In other Beta Bionics news, Director Adam Lezack sold 1,406 shares of the company’s stock in a transaction dated Friday, October 31st. The stock was sold at an average price of $26.87, for a total value of $37,779.22. Following the transaction, the director directly owned 9,841 shares of the company’s stock, valued at $264,427.67. This represents a 12.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Mike Mensinger sold 1,063 shares of Beta Bionics stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $29.34, for a total value of $31,188.42. Following the sale, the insider owned 90,752 shares of the company’s stock, valued at approximately $2,662,663.68. This represents a 1.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 25,302 shares of company stock worth $568,505.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Tudor Investment Corp ET AL acquired a new stake in shares of Beta Bionics in the 3rd quarter valued at $767,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Beta Bionics in the third quarter worth about $775,000. Dark Forest Capital Management LP acquired a new stake in shares of Beta Bionics in the third quarter worth about $1,118,000. Verition Fund Management LLC boosted its stake in shares of Beta Bionics by 4.0% during the 3rd quarter. Verition Fund Management LLC now owns 47,299 shares of the company’s stock worth $940,000 after acquiring an additional 1,823 shares in the last quarter. Finally, Vestal Point Capital LP increased its holdings in shares of Beta Bionics by 9.1% during the 3rd quarter. Vestal Point Capital LP now owns 600,000 shares of the company’s stock valued at $11,922,000 after acquiring an additional 50,000 shares during the last quarter.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.